Faricimab

Therapeutic indications

Faricimab is indicated for:

Neovascular (wet) age-related macular degeneration (nAMD)

Population group: only adults (18 years old or older)

Exudative age-related macular degeneration

For this indication, competent medicine agencies globally authorize below treatments (click for details):

6 mg every 4 weeks for the first 4 doses, after 20-24 weeks assessment of disease activity and administration of 6 mg every 8, 12 or 16 weeks

Visual impairment due to diabetic macular oedema (DME)

Population group: only adults (18 years old or older)

Diabetic macular edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

6 mg every 4 weeks for the first 4 doses, thereafter the dosing interval may be extended up to every 16 weeks in increments of up to 4 weeks

Contraindications

Faricimab is contraindicated in the following cases:

Active intraocular inflammation

Uveitis

Active or suspected ocular or periocular infections

at least one of

Eye infection
Infection of skin of eyelid and periocular region

Concomitant use of other anti-VEGF

Anti-angiogenic medicinal products

Rhegmatogenous retinal detachment, stage 3 or 4 macular holes, retinal break

at least one of

Rhegmatogenous retinal detachment
Full thickness macular hole stage III
Full thickness macular hole stage IV
† Retinal defect

Patients with treatment related decrease in Best Corrected Visual Acuity (BCVA)

Reduced visual acuity

Intraocular pressure of ≥30 mmHg

Raised intraocular pressure

Subretinal haemorrhage

Subretinal hemorrhage

Intraocular surgery

Surgical procedure on eye proper

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.